Mega LifeSciences
Mega LifeSciences, also known as Mega We Care, is a prominent player in the healthcare industry, headquartered in Thailand. Founded in 1985, the company has established a strong presence across Southeast Asia, with significant operations in countries such as Myanmar, Vietnam, and Malaysia. Specialising in the development and distribution of high-quality pharmaceuticals, dietary supplements, and herbal products, Mega LifeSciences is recognised for its commitment to innovation and quality. The company’s unique formulations and extensive product range cater to diverse health needs, setting it apart in a competitive market. With a focus on enhancing health and well-being, Mega LifeSciences has achieved notable milestones, including numerous certifications and awards that underscore its market position as a trusted provider in the healthcare sector.
DitchCarbon Score
How does Mega LifeSciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mega LifeSciences's score of 33 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mega LifeSciences's reported carbon emissions
In 2023, Mega LifeSciences reported total carbon emissions of approximately 9,000,980 kg CO2e. This figure includes 1,808,570 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and 6,752,890 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. Additionally, Scope 3 emissions accounted for about 439,530 kg CO2e, which includes all other indirect emissions that occur in the value chain. Comparatively, in 2022, the company had total emissions of approximately 627,413,270 kg CO2e, with Scope 1 emissions at 633,276,080 kg CO2e, Scope 2 emissions at 5,504,540 kg CO2e, and Scope 3 emissions at 358,280 kg CO2e. This indicates a significant increase in total emissions from 2022 to 2023. Currently, Mega LifeSciences has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented reduction targets suggests that the company may be in the early stages of developing a comprehensive climate strategy. As the industry increasingly prioritises sustainability, it will be essential for Mega LifeSciences to establish clear commitments to reduce emissions and enhance their climate resilience.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 633,276,080 | 0,000,000 |
| Scope 2 | 5,504,540 | 0,000,000 |
| Scope 3 | 358,280 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mega LifeSciences is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
